Toi M - Search Results

1

Adjuvant S-1 plus endocrine therapy for oestrogen receptor-positive, HER2-negative, primary breast cancer: a multicentre, open-label, randomised, controlled, phase 3 trial.

Toi M, Imoto S, Ishida T, Ito Y, Iwata H, Masuda N, Mukai H, Saji S, Shimizu A, Ikeda T, Haga H, Saeki T, Aogi K, Sugie T, Ueno T, Kinoshita T, Kai Y, Kitada M, Sato Y, Jimbo K, Sato N, Ishiguro H, Takada M, Ohashi Y, Ohno S. Toi M, et al. Lancet Oncol. 2021 Jan;22(1):74-84. doi: 10.1016/S1470-2045(20)30534-9. Lancet Oncol. 2021. PMID: 33387497 Clinical Trial.

2

Randomized adjuvant trial to evaluate the addition of tamoxifen and PSK to chemotherapy in patients with primary breast cancer. 5-Year results from the Nishi-Nippon Group of the Adjuvant Chemoendocrine Therapy for Breast Cancer Organization.

Toi M, Hattori T, Akagi M, Inokuchi K, Orita K, Sugimachi K, Dohi K, Nomura Y, Monden Y, Hamada Y, et al. Toi M, et al. Cancer. 1992 Nov 15;70(10):2475-83. doi: 10.1002/1097-0142(19921115)70:10<2475::aid-cncr2820701014>3.0.co;2-p. Cancer. 1992. PMID: 1423177 Clinical Trial.

3

Prospective randomized controlled study on bestatin in resectable gastric cancer--third report.

Niimoto M, Saeki T, Toi M, Nishiyama M, Hirai T, Yanagawa E, Hattori T. Niimoto M, et al. Among authors: toi m. Jpn J Surg. 1990 Mar;20(2):186-91. doi: 10.1007/BF02470767. Jpn J Surg. 1990. PMID: 2111415 Clinical Trial.

4

The discrepancy between immunocytochemical and biochemical assay of estrogen receptor in breast cancer patients treated by endocrine therapy.

Toi M, Nakamura T, Wada T, Yamamoto A, Toge T, Niimoto M, Hattori T. Toi M, et al. Jpn J Surg. 1989 Nov;19(6):768-72. doi: 10.1007/BF02471732. Jpn J Surg. 1989. PMID: 2514309

5

[Combination chemotherapy of CPM-MTX-5-FU in non-resectable and recurrent cancer patients].

Saeki T, Jinushi K, Kim R, Toi M, Saeki K, Yoshinaka K, Yanagawa E, Niimoto M, Hattori T. Saeki T, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1989 Apr;16(4 Pt 1):827-31. Gan To Kagaku Ryoho. 1989. PMID: 2712579 Japanese.

6

Role of epidermal growth factor receptor expression in primary breast cancer: results of a biochemical study and an immunocytochemical study.

Toi M, Tominaga T, Osaki A, Toge T. Toi M, et al. Breast Cancer Res Treat. 1994 Jan;29(1):51-8. doi: 10.1007/BF00666181. Breast Cancer Res Treat. 1994. PMID: 7912567 Clinical Trial.

7

Regulation of endothelial growth factor expressions in breast cancer.

Toi M, Yamamoto Y, Taniguchi T, Saji S, Hayashi K, Tominaga T. Toi M, et al. Gan To Kagaku Ryoho. 1996 Mar;23 Suppl 1:75-9. Gan To Kagaku Ryoho. 1996. PMID: 8702315

8

[The importance of tumor angiogenesis as a prognostic indicator in primary breast cancer].

Saji S, Toi M, Tominaga T. Saji S, et al. Among authors: toi m. Nihon Geka Gakkai Zasshi. 1996 May;97(5):368-74. Nihon Geka Gakkai Zasshi. 1996. PMID: 8709939 Review. Japanese.

9

[The feasibility of CEF (cyclophosphamide, epirubicin, 5-FU) regimen in the adjuvant setting of primary breast cancer].

Honda S, Toi M, Shimizu S, Hayashi K, Tominaga T. Honda S, et al. Among authors: toi m. Gan To Kagaku Ryoho. 1997 Apr;24(6):679-83. Gan To Kagaku Ryoho. 1997. PMID: 9126304 Clinical Trial. Japanese.

10

[New molecular target of cancer therapy--angiogenesis regulator VEGF].

Toi M, Ueno T, Tominaga T. Toi M, et al. Gan To Kagaku Ryoho. 1997 Dec;24(15):2202-6. Gan To Kagaku Ryoho. 1997. PMID: 9422062 Review. Japanese.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

786 results

Search Page

Filters